Navigation Links
Quintiles to Open Clinical Research Office in Wilmington, NC
Date:1/17/2008

Growth driving second new office opening in North Carolina in last 12

months

RESEARCH TRIANGLE PARK, N.C., Jan. 17 /PRNewswire/ -- Quintiles Transnational Corp. today announced that the global leader in pharmaceutical services will open an office in Wilmington, N.C. The new office is an expansion of Quintiles' clinical research in pharmaceutical and biotechnology development.

The new Wilmington office is Quintiles' second expansion within the state in the last 12 months. Last January, Quintiles opened a data processing center in Williamston, N.C.

"With a strong educational system and a positive environment for business, North Carolina is clearly the leading location for global clinical research organizations," said Mike Mortimer, Executive Vice President and Chief Administrative Officer. "We were founded in the Research Triangle more than 25 years ago, and we've fueled our growth by tapping into an excellent work force like that in North Carolina, with people committed to improving health care around the world. Our employees find Quintiles to be a place for fulfilling, rewarding work and in return they are driving the company to great success."

The Wilmington office is centrally located in the North State Bank Building, 1411 Commonwealth Drive, convenient to major thoroughfares and the Wilmington airport, and not far from Wrightsville Beach. Quintiles will occupy two of the three stories of the bank building.

Founded in 1982 by current CEO and Chairman Dennis Gillings, CBE, the company is considered a pioneer in clinical research. Quintiles is the largest provider of pharmaceutical services in the world, with more than 19,000 employees in more than 50 countries. More than 1,500 are employed in North Carolina.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 19,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.quintiles.com.


'/>"/>
SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
2. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
3. Expert Cardiologist Joins Quintiles Medical Group
4. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
5. YM BioSciences provides update on AeroLEF(TM) clinical development program
6. Irving Dark Named Vice President of Cytel Clinical Research Services
7. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
8. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
9. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
10. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
11. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):